Plasma Fractionation Market Current Trends, Research Analysis and Projections For 2019-2028
Blood plasma constitutes primarily of water, salts, minerals, etc. and is derived from blood. Approximately 55% of the total blood volume is made up of plasma. Proteins such as immunoglobulins and fibrinogen along with some others can be found in blood plasma. Plasma fractionation is the process of separation of various components present in blood, and is used in treatment of protein deficiency in individuals. It can also be used as a packaging material in various industrial applications.
Major factor driving growth of the global plasma fractionation market is increasing incidence of alpha-1 antitrypsin deficiency (ATTD) and respiratory diseases among individuals in developed and developing economies. Apart from this, factors such as Increasing use of immunoglobulins in various therapeutic areas and growing geriatric population across the globe are expected to fuel growth of the global market. But, unfavorable reimbursement policies in some developed economies coupled with high costs associated with plasma fractionation are other factors anticipated to hamper growth of the global market to a significant extent.
The global plasma fractionation market report has been segmented on the basis of product type, application, end user, and region. On the basis of region, the global plasma fractionation market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Global plasma fractionation market segmentation:
By product type:
- Coagulation factor concentrates
- Critical Care
By end user:
- Hospitals and Clinics
- Clinical Research Laboratories
- Academic Institutes
Get Free Sample Copy Of This Research @ https://marketresearch.biz/report/plasma-fractionation-market/request-sample/
The market in North America accounted for highest revenue share in the global plasma fractionation market, as compared to markets in other regions. This can be attributed to, availability of proper healthcare infrastructure and increasing use of immunoglobulins in treatment of neurological diseases in countries in the region. The market in Asia Pacific is projected to witness substantial growth over the forecast period, registering highest CAGR. High prevalence of hemophilia and increasing collection of blood plasma in emerging economies such as China, India, and South Korea are factors responsible for Asia Pacific market witness high growth. Moreover, presence of a large geriatric population pool is another factor expected to aid in growth of the Asia Pacific plasma fractionation market to a significant extent.
Prominent players in the global plasma fractionation market include CSL Plasma, Inc., Grifols, Shire (BioLife Plasma Services), Octapharma Plasma, Inc., Kedrion S.p.A, Bio Product Laboratory Ltd., LFB S.A., Biotest Pharmaceuticals Corporation, Japan Blood Products Organization, and China Biologic Products Holdings, Inc.